| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2006 | Dec, 2005 | Dec, 2004 |
| Sales | 0 | 0 | 26,850 | 12,540 | 5,370 |
| Sales Growth | unch | -100.00% | +114.11% | +133.52% | -85.94% |
| Net Income | -31,570 | -17,520 | -49,070 | -96,490 | -38,900 |
| Net Income Growth | -80.19% | +64.30% | +49.15% | -148.05% | -14.61% |
Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. NervGen Pharma Corp. is based in VANCOUVER, British Columbia.
Fiscal Year End Date: 12/31